Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Anticancer Research Year : 2010

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Abstract

For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.

Domains

Immunology
Not file

Dates and versions

inserm-00555027 , version 1 (12-01-2011)

Identifiers

  • HAL Id : inserm-00555027 , version 1
  • PUBMED : 21036758

Cite

Sylvain Ladoire, Jean-Christophe Eymard, Sylvie Zanetta, Grégoire Mignot, Etienne Martin, et al.. Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.. Anticancer Research, 2010, 30 (10), pp.4317-23. ⟨inserm-00555027⟩
125 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More